CHADDS FORD, Pa. - Drug developer Endo Pharmaceuticals Holdings Inc. on Thursday named Alan G. Levin executive vice president and chief financial officer to replace the position left open by Charles Rowland.
Rowland resigned to pursue other interests in September.
Levin will become chief financial officer June 1. He was previously a chief financial officer at Moksha8 Pharmaceuticals Inc., a privately held pharmaceuticals company focusing on emerging markets. He has also previously worked at Pfizer.
Shares of Endo rose 15 cents to close at $16.29.
Rowland resigned to pursue other interests in September.
Levin will become chief financial officer June 1. He was previously a chief financial officer at Moksha8 Pharmaceuticals Inc., a privately held pharmaceuticals company focusing on emerging markets. He has also previously worked at Pfizer.
Shares of Endo rose 15 cents to close at $16.29.
No comments:
Post a Comment